Compare FUNC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUNC | MGNX |
|---|---|---|
| Founded | 1900 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.6M | 280.3M |
| IPO Year | 2012 | 2013 |
| Metric | FUNC | MGNX |
|---|---|---|
| Price | $44.30 | $4.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 9.6K | ★ 469.4K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 19.68 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | $18,426,000.00 | ★ $149,500,000.00 |
| Revenue This Year | $13.05 | N/A |
| Revenue Next Year | $6.56 | $3.19 |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $33.54 | $1.30 |
| 52 Week High | $46.30 | $5.08 |
| Indicator | FUNC | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 56.31 |
| Support Level | $43.48 | $3.80 |
| Resistance Level | $46.14 | $4.38 |
| Average True Range (ATR) | 1.13 | 0.19 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 72.16 | 74.17 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.